bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
A bursa is a small fluid-filled sac made of white fibrous tissue and lined with synovial membrane. Bursa may also be formed by a synovial membrane that extends outside of the joint capsule. It provides a cushion between bones and tendons or muscles around a joint; bursa are filled with synovial fluid and are found around almost every major joint of the body.
The ability to create precise and carefully controlled chemoattractant gradients makes microfluidics the ideal tool to study motility, chemotaxis and the ability to evolve / develop resistance to antibiotics in small populations of microorganisms and in a short period of time. These microorganisms including bacteria and the broad range of organisms that form the marine microbial loop, responsible for regulating much of the oceans' biogeochemistry. Microfluidics has also greatly aided the study of durotaxis by facilitating the creation of durotactic (stiffness) gradients.
Since Xi became general secretary, censorship has stepped up. Xi has overseen the increased coordination and consolidation of censorship authorities, raising their efficiency, and under his leadership censorship practices have tightened. Xi has called on for more positive energy at Chinese media, referring to the need for uplifting messages as opposed to critical or negative ones. In August 2013, he gave what became known as the August 19 speech, emphasizing the guiding role of ideology in propaganda. At the Symposium on News Reporting and Public Opinion in 2016, Xi stated that "party and government-owned media must hold the family name of the party" and that the state media "must embody the party's will, safeguard the party's authority". Xi's administration has overseen more Internet restrictions imposed, and is described as being "stricter across the board" on speech than previous administrations. In 2013, the State Internet Information Office summoned influential bloggers to a seminar to instruct them to avoid writing about politics, the CCP, or making statements contradicting official narratives. Many bloggers stopped writing about controversial topics, and Weibo went into decline, with much of its readership shifting to WeChat users speaking to limited social circles. The SIIO also formulated the Seven Bottom Lines, which serve as the bottom lines that internet users and social media companies in China must adhere to.
From May 2004 to April 2012, Surya Mohapatra served as the company's President and CEO. In 2007 Quest acquired diagnostic testing equipment company AmeriPath. In response to Mohapatra's resignation after eight years with Quest, former Philips Healthcare CEO Stephen Rusckowski was appointed. Under Rusckowski, Quest Diagnostics teamed up with central New England's largest health care system, UMass Memorial Health Care, to purchase its clinical outreach laboratory.
Sources: en.wikipedia.org
=== Cautions === Non-selective beta-blockers should be avoided in people with asthma or bronchospasm as they may cause exacerbations and worsening of symptoms. β1 selective beta-blockers like bisoprolol have not been shown to cause an increase in asthma exacerbations, and may be cautiously tried in those with controlled, mild-to-moderate asthma with cardiac comorbidities. A 2014 meta-analysis found that unlike non-selective beta-blockers, β1 selective beta-blockers (bisoprolol) showed only a small impact on lung function, with patients remaining responsive to salbutamol (β2 -agonist) rescue therapy and endorses the use of bisoprolol in select patients with controlled asthma. This was supported by a 2020 clinical trial where bisoprolol had no significant impact on bronchodilation post salbutamol administration.
== Research == Other therapies are under investigation, including gene therapy. BioMarin is conducting clinical trials to investigate PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase or 'PAL'), which is an enzyme substitution therapy in which the missing PAH enzyme is replaced with an analogous enzyme that also breaks down Phe (to ammonia and trans-cinnamic acid). PEG-PAL was in Phase 2 clinical development as of 2015, but was put on clinical hold in September 2021. In February 2022, the FDA issued a statement requiring further data from non-clinical studies to assess oncogenic risk resulting from PEG-PAL treatments.
I think "Sickman" is not that bad. I thought most of the hassle would come from "Junkhead" and "Godsmack". Those songs are put in sequence on the second side those five songs from "Junkhead" to "Angry Chair" for a reason: Because it tells a story. It starts out with a really young naive attitude with "Junkhead", like drugs are great, sex is great, rock'n' roll, yeah! Then, as it progresses, there's a little bit of growing up and a little bit of a realization of what it's about, and that ain't what it's about. I've been using this phrase a lot, but it makes a lot of sense: It's really easy to die; it's really hard to live. It takes a lot of guts to live. It doesn't take a lot of guts to die. Those five and "Sickman" are the only ones talking about that type of mentality [drugs]. The rest of the stuff is not like that at all. "Rain When I Die" is a song to a girl. There's a lot of stuff on it. A good portion of it is a story, and it's meant to be that way. It's kind of overwhelming and unpleasant at times, unsettling maybe, but that's why all those songs are together. Even if it's disturbing, it's not something anybody else needs to worry about or the way somebody else needs to live their life. In the liner notes of 1999's Music Bank box set collection, Cantrell cited "Junkhead" and "God Smack" as "the most openly honest" songs about drug use. Cantrell said he wrote "Them Bones" about "mortality, that one of these days we'll end up a pile of bones." He told RIP magazine in 1993: "'Them Bones' is pretty cut and dried.
Computational neurogenetic modeling is concerned with the development of dynamic neuronal models for modeling brain functions with respect to genes and dynamic interactions between genes, on the cellular level (Computational Neurogenetic Modeling (CNGM) can also be used to model neural systems).
=== Film adaptation === A film adaptation has been in development hell since 2013, and it was reported on May 25, 2021, that the project is still in development by J.J. Abrams and Bad Robot and the script has been written. As of 2022, J.J. Abrams continued to express interest in bringing Portal to film. In 2026, Kane Parsons also expressed interest in directing a Portal film.
Sources: en.wikipedia.org
Relugolix is a selective antagonist of the gonadotropin-releasing hormone receptor (GnRHR), with a half-maximal inhibitory concentration (IC50) of 0.12 nM. A dosage of relugolix of 40 mg once per day has been found to suppress estradiol levels to postmenopausal levels (<20 pg/mL) within 24 hours in premenopausal women. In the control group of women, estradiol levels fluctuated between 50 and 250 pg/mL. Estradiol levels have been found to return to normal concentrations within 4 weeks of discontinuation of relugolix in premenopausal women. The medication additionally suppresses levels of progesterone, luteinizing hormone, and follicle-stimulating hormone in premenopausal women. Relugolix at a dosage of 40 mg or more once per day has been found to reduce testosterone levels to sustained castrate levels (<20 ng/dL) in men. It additionally suppresses luteinizing hormone and follicle-stimulating hormone levels in men. Lower doses of relugolix (<40 mg/day) are under investigation for achieving partial sex hormone suppression in the treatment of endometriosis and uterine fibroids. This is intended to reduce the incidence and severity of menopausal symptoms such as hot flushes and decreased bone mineral density that are secondary to estrogen deficiency.
=== Pandora Papers === The October 2021 leak of more than 11.9 million documents by the International Consortium of Investigative Journalists (ICIJ) mentioned Sheikh Hazza as one of the Emirati royals with offshore holdings. The former national security adviser of the UAE reportedly owned the H Hotel office tower at 1 Sheikh Zayed Road, which gave space to at least four companies that provided offshore clients with financial or company formation services. Amongst these firms was SFM Corporate Services that had its office in the building until 2017. The ICIJ report said that SFM provided its services to owners of at least 2,977 firms in the UAE, the British Virgin Islands and other offshore financial centres. It was also revealed that Sheikh Hazza had his own offshore companies outside the UAE. In 2016, an Emirati law firm, Hadef & Partners assisted Sheikh Hazza to incorporate a UAE Company named Loomington Investments Ltd. The report revealed that two other companies with same name in the British Virgin Islands and Seychelles were owned by Sheikh Hazza.
=== Biosensors === Graphene does not oxidize in air or in biological fluids, making it an attractive material for use as a biosensor. A graphene circuit can be configured as a field effect biosensor by applying biological capture molecules and blocking layers to the graphene, then controlling the voltage difference between the graphene and the liquid that includes the biological test sample. Of the various types of graphene sensors that can be made, biosensors were the first to be available for sale.
=== Ancient Cambodian glaze === Research on Khmer Antique glazing and techniques - Antique Khmer ceramics are renowned, but the technology was lost during the recent terrible upheavals in Cambodia (Khmer Rouge). The center has sought to rediscover this technology, researching antique Khmer glazing, bisque, kilns, potters language etc.
glutathione + a lactate The catalysis of S-lactoylglutathione hydrolysis by glutathione thiolesterase has been noted in Saccharomyces cerevisiae. Additionally, human red blood cells have been found to contain at least four separate glutathione thiol esterases. The enzymes found supported the potential substrate activity of S-lactoylglutathione and S-propionylglutathione.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.